On April 22, 2016 researchers have identified a potential alternative approach to blocking the activity of a key molecular driver of an advanced form of prostate cancer, called androgen-independent or castration-resistant prostate cancer.
In prostate cancer cell lines and in several mouse models of prostate cancer, treatment with drug-like small molecules that target a protein called ROR-γ disrupted the activity of the androgen receptor (AR), the researchers showed. Signaling through AR is the chief means by which prostate cancer cells grow and spread. Read more here.
No comments:
Post a Comment